Ross shares how Biosortia is unlocking previously unobtainable, drug-like small molecules directly from microbiomes—transforming how therapeutics, agrochemicals, longevity science, and life sciences approach discovery and de-risking.

We discuss why scale is the real innovation advantage, how accessing the “hidden chemistry of life” changes the economics of drug discovery by orders of magnitude, and what it takes to turn deep science into partner-ready IP with complete AI datasets.

A must-listen for founders, investors, and innovation leaders navigating the future of biotech, AI, and monetizable science.